北大医药(000788) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was CNY 487.01 million, a decrease of 7.16% compared to CNY 524.56 million in the same period last year[8] - Net profit attributable to shareholders was CNY 15.13 million, representing a 3.46% increase from CNY 14.62 million year-on-year[8] - The total operating revenue for Q1 2019 was CNY 487,014,401.13, a decrease of 7.14% from CNY 524,561,601.68 in the same period last year[44] - Net profit for Q1 2019 was CNY 15,126,964.87, an increase of 3.47% compared to CNY 14,619,756.56 in Q1 2018[46] - The total operating profit for Q1 2019 was CNY 15,938,908.67, an increase from CNY 13,328,167.22 in the previous year, representing a growth of approximately 19.6%[50] - The total comprehensive income for Q1 2019 was CNY 13,272,973.66, which is an increase from CNY 11,411,728.34 in the same quarter last year, showing a growth of approximately 16.3%[51] Cash Flow - The net cash flow from operating activities increased by 216.94%, reaching CNY 113.33 million, compared to a negative cash flow of CNY 96.92 million in the previous year[8] - Cash flow from operating activities generated a net amount of CNY 113,334,438.60, a significant recovery from a negative cash flow of CNY -96,916,123.06 in the previous year[54] - The net cash flow from investing activities improved by 66.98%, with a net outflow of ¥981,763.19 compared to ¥2,973,679.20 in the previous year[17] - The company’s investment activities resulted in a net cash outflow of CNY 981,763.19, compared to CNY 2,973,679.20 in the previous year, indicating a reduction in investment spending[54] - The company’s financing activities generated a net cash flow of ¥15,137,662.97, a decrease of 47.77% from ¥28,980,668.74 in the previous year due to increased loan repayments[17] - The net cash flow from financing activities was 130,711,526.67, compared to a negative cash flow of -68,959,673.95 in the previous year[59] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 2.17 billion, an increase of 1.09% from CNY 2.14 billion at the end of the previous year[8] - The total current assets amounted to CNY 1,922,664,022.00, an increase from CNY 1,896,206,237.70 at the end of 2018[36] - Total liabilities as of March 31, 2019, were CNY 942,239,467.90, slightly up from CNY 933,890,145.00 at the end of 2018[38] - Total liabilities for Q1 2019 were CNY 252,103,717.29, a decrease of 7.19% from CNY 271,560,898.90 in the previous quarter[43] - The total equity attributable to shareholders increased to CNY 1,229,016,238.45 from CNY 1,213,973,541.78, showing a growth of about 1.2%[39] Research and Development - The company is advancing its consistency evaluation R&D projects and expects to launch several projects within the year[8] - Research and development expenses decreased by 44.69% year-on-year to ¥841,936.81, down from ¥1,522,234.39 in the previous year[17] - Research and development expenses for Q1 2019 were CNY 841,936.81, down from CNY 1,522,234.39 in the same period last year[44] - The company is collaborating with SK Biopharmaceuticals and others on the development of the innovative drug SKL-PSL, which has received clinical approval but has not yet started clinical trials[19] - The company has committed to pay ¥27.5 million for the development of a new drug, with ¥4.125 million already paid as of the report date[20] Contracts and Collaborations - The company has signed a long-term service contract with Peking University International Hospital, with an estimated total contract value of ¥1 billion per year for three years[22] - The company has engaged with top-tier venture capital teams in the pharmaceutical and medical fields, with potential future disclosures on progress[8] Other Financial Metrics - The basic earnings per share for the period was CNY 0.0254, up 3.67% from CNY 0.0245 in the same period last year[8] - The company reported a 35.62% decrease in taxes payable, amounting to ¥21,565,768.72, compared to ¥33,498,260.20 at the end of 2018[17] - The company incurred operating cash outflows totaling CNY 621,999,207.75, compared to CNY 607,537,132.94 in the previous year, indicating a slight increase of about 2.3%[54] - The company’s tax expenses for the quarter were CNY 2,689,997.52, an increase from CNY 1,917,888.88 in the previous year, representing a rise of approximately 40.2%[50] Equity Transactions - The company is in the process of transferring 41% equity in Beijing Peking University Medical Oncology Hospital Management Co., Ltd., with the transaction not yet completed[25] Compliance and Governance - There were no violations regarding external guarantees during the reporting period[31] - The company did not engage in derivative investments during the reporting period[29] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32] - The company did not undergo an audit for the first quarter report[60]